145 related articles for article (PubMed ID: 18271660)
21. Role of leukocytapheresis in the management of inflammatory bowel disease.
Fukunaga K; Miwa H; Matsumoto T
Trop Gastroenterol; 2007; 28(1):11-5. PubMed ID: 17896603
[TBL] [Abstract][Full Text] [Related]
22. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
Jeuring SFG; Biemans VBC; van den Heuvel TRA; Zeegers MP; Hameeteman WH; Romberg-Camps MJL; Oostenbrug LE; Masclee AAM; Jonkers DMAE; Pierik MJ
Am J Gastroenterol; 2018 Mar; 113(3):384-395. PubMed ID: 29317770
[TBL] [Abstract][Full Text] [Related]
23. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study.
Hanai H; Watanabe F; Takeuchi K; Iida T; Yamada M; Iwaoka Y; Saniabadi A; Matsushita I; Sato Y; Tozawa K; Arai H; Furuta T; Sugimoto K; Bjarnason I
Clin Gastroenterol Hepatol; 2003 Jan; 1(1):28-35. PubMed ID: 15017514
[TBL] [Abstract][Full Text] [Related]
24. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease.
Maté-Jiménez J; Hermida C; Cantero-Perona J; Moreno-Otero R
Eur J Gastroenterol Hepatol; 2000 Nov; 12(11):1227-33. PubMed ID: 11111780
[TBL] [Abstract][Full Text] [Related]
25. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease.
Matsuda R; Koide T; Tokoro C; Yamamoto T; Godai T; Morohashi T; Fujita Y; Takahashi D; Kawana I; Suzuki S; Umemura S
Inflamm Bowel Dis; 2009 Mar; 15(3):328-34. PubMed ID: 18942752
[TBL] [Abstract][Full Text] [Related]
26. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives.
Ruuska T; Wewer V; Lindgren F; Malmborg P; Lindquist M; Marthinsen L; Browaldh L; Casswall T; Kalliomäki M; Grönlund J
Inflamm Bowel Dis; 2009 Jul; 15(7):1049-54. PubMed ID: 19137602
[TBL] [Abstract][Full Text] [Related]
28. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study.
Suzuki Y; Yoshimura N; Saniabadi AR; Saito Y
Dig Dis Sci; 2004 Apr; 49(4):565-71. PubMed ID: 15185858
[TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis.
Kanke K; Nakano M; Hiraishi H; Terano A
Dig Liver Dis; 2004 Dec; 36(12):811-7. PubMed ID: 15646427
[TBL] [Abstract][Full Text] [Related]
30. CD8
Dai SX; Gu HX; Lin QY; Huang SZ; Xing TS; Zhang QF; Wu G; Chen MH; Tan WE; Jian HJ; Zheng ZW; Zhong T; Zhang MH; Cheng XF; Huang P; Liao GJ; Sha WH
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):693-702. PubMed ID: 28502591
[TBL] [Abstract][Full Text] [Related]
31. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis.
Dignass A; Akbar A; Baumgart DC; Bommelaer G; Bouguen G; Cadiot G; Gillessen A; Grimaud JC; Hart A; Hoque S; Makins R; Michiels C; Moreau J; Premchand P; Ramlow W; Schanz S; Subramanian S; von Tirpitz C; Bonaz B
Scand J Gastroenterol; 2018 Apr; 53(4):442-448. PubMed ID: 29513111
[TBL] [Abstract][Full Text] [Related]
32. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
Pearce CB; Lawrance IC
J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
[TBL] [Abstract][Full Text] [Related]
33. Current therapy of inflammatory bowel disease in children.
Rufo PA; Bousvaros A
Paediatr Drugs; 2006; 8(5):279-302. PubMed ID: 17037946
[TBL] [Abstract][Full Text] [Related]
34. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?
Saniabadi AR; Hanai H; Suzuki Y; Ohmori T; Sawada K; Yoshimura N; Saito Y; Takeda Y; Umemura K; Kondo K; Ikeda Y; Fukunaga K; Nakashima M; Beretta A; Bjarnason I; Lofberg R
J Clin Apher; 2005 Oct; 20(3):171-84. PubMed ID: 15892107
[TBL] [Abstract][Full Text] [Related]
35. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease.
Ng SC; Arebi N; Kamm MA
Inflamm Bowel Dis; 2007 Feb; 13(2):129-34. PubMed ID: 17206694
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study.
Yokoyama Y; Watanabe K; Ito H; Nishishita M; Sawada K; Okuyama Y; Okazaki K; Fujii H; Nakase H; Masuda T; Fukunaga K; Andoh A; Nakamura S
Cytotherapy; 2015 May; 17(5):680-8. PubMed ID: 25804800
[TBL] [Abstract][Full Text] [Related]
37. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study.
Fukuda Y; Matsui T; Suzuki Y; Kanke K; Matsumoto T; Takazoe M; Matsumoto T; Motoya S; Honma T; Sawada K; Yao T; Shimoyama T; Hibi T
J Gastroenterol; 2004 Dec; 39(12):1158-64. PubMed ID: 15622479
[TBL] [Abstract][Full Text] [Related]
38. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis.
Yamamoto T; Umegae S; Matsumoto K
World J Gastroenterol; 2006 Jan; 12(4):520-5. PubMed ID: 16489663
[TBL] [Abstract][Full Text] [Related]
39. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients.
Bodelier AG; Pierik MJ; Lenaerts K; de Boer E; Olde Damink SW; Hameeteman WM; Masclee AA; Jonkers DM
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):807-13. PubMed ID: 26919325
[TBL] [Abstract][Full Text] [Related]
40. A Two-Week Fecal Microbiota Transplantation Course in Pediatric Patients with Inflammatory Bowel Disease.
Karolewska-Bochenek K; Grzesiowski P; Banaszkiewicz A; Gawronska A; Kotowska M; Dziekiewicz M; Albrecht P; Radzikowski A; Lazowska-Przeorek I
Adv Exp Med Biol; 2018; 1047():81-87. PubMed ID: 29151253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
